IDO1 and melanoma: However, the combination of IDO-1 inhibition and immunotherapy may be dubious given that IDO-1 inhibition combined with pembrolizumab failed to show any benefit over pembrolizumab alone in a phase 3 trial for advanced melanoma despite promising pre-clinical data [80].